Literature DB >> 21542760

Iniparib in metastatic triple-negative breast cancer.

Pawel Domagala, Jan Lubinski, Wenancjusz Domagala.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21542760     DOI： 10.1056/NEJMc1101855

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Authors:  Haiying Cheng; Zhenfeng Zhang; Alain Borczuk; Charles A Powell; Adayabalam S Balajee; Howard B Lieberman; Balazs Halmos
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

2.  Nuclear PARP1 expression and its prognostic significance in breast cancer patients.

Authors:  Annalisa Mazzotta; Giulia Partipilo; Simona De Summa; Francesco Giotta; Giovanni Simone; Anita Mangia
Journal:  Tumour Biol       Date:  2015-11-27

3.  Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.

Authors:  Lili Zhai; Shuai Li; Huilan Li; Yi Zheng; Ronggang Lang; Yu Fan; Feng Gu; Xiaojing Guo; Xinmin Zhang; Li Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.

Authors:  Wei Qiu; Robert Lam; Oleksandr Voytyuk; Vladimir Romanov; Roni Gordon; Simon Gebremeskel; Jakub Vodsedalek; Christine Thompson; Irina Beletskaya; Kevin P Battaile; Emil F Pai; Robert Rottapel; Nickolay Y Chirgadze
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-09-27

5.  Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.

Authors:  Chandra Bhushan Prasad; Shyam Babu Prasad; Suresh Singh Yadav; Laxmi Kant Pandey; Sunita Singh; Satyajit Pradhan; Gopeshwar Narayan
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

6.  NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.

Authors:  Anita Mangia; Emanuela Scarpi; Giulia Partipilo; Laura Schirosi; Giuseppina Opinto; Francesco Giotta; Giovanni Simone
Journal:  Oncotarget       Date:  2017-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.